Insulet (NASDAQ:PODD) Price Target Raised to $275.00 at Citigroup

Insulet (NASDAQ:PODD) had its price objective lifted by Citigroup from $250.00 to $275.00 in a report released on Tuesday morning, Benzinga reports. They currently have a buy rating on the medical instruments supplier’s stock.

A number of other analysts also recently commented on PODD. Piper Sandler boosted their price target on shares of Insulet from $230.00 to $285.00 and gave the stock an overweight rating in a research report on Tuesday, September 17th. UBS Group boosted their target price on Insulet from $211.00 to $223.00 and gave the stock a neutral rating in a report on Friday, August 9th. BTIG Research decreased their price target on Insulet from $270.00 to $250.00 and set a buy rating for the company in a research note on Friday, August 9th. Canaccord Genuity Group lifted their price target on Insulet from $236.00 to $269.00 and gave the company a buy rating in a research report on Wednesday, September 25th. Finally, Barclays upped their price objective on Insulet from $200.00 to $220.00 and gave the company an equal weight rating in a report on Monday, August 12th. Four analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of Moderate Buy and an average price target of $234.60.

Insulet Stock Down 1.1 %

PODD opened at $229.99 on Tuesday. The stock’s 50 day moving average price is $209.10 and its 200 day moving average price is $191.75. The company has a debt-to-equity ratio of 1.36, a current ratio of 3.60 and a quick ratio of 2.71. The stock has a market cap of $16.11 billion, a P/E ratio of 69.69, a P/E/G ratio of 4.34 and a beta of 1.21. Insulet has a 12 month low of $125.82 and a 12 month high of $243.98.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 EPS for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.01). Insulet had a net margin of 21.11% and a return on equity of 30.73%. The business had revenue of $488.50 million for the quarter, compared to analyst estimates of $488.00 million. During the same period last year, the business posted $0.38 earnings per share. Insulet’s revenue for the quarter was up 23.2% on a year-over-year basis. As a group, research analysts predict that Insulet will post 3.04 earnings per share for the current year.

Institutional Trading of Insulet

A number of hedge funds have recently bought and sold shares of PODD. Diversified Trust Co raised its holdings in shares of Insulet by 90.9% during the second quarter. Diversified Trust Co now owns 9,130 shares of the medical instruments supplier’s stock valued at $1,842,000 after acquiring an additional 4,348 shares during the period. SG Americas Securities LLC lifted its holdings in shares of Insulet by 349.3% in the first quarter. SG Americas Securities LLC now owns 29,575 shares of the medical instruments supplier’s stock valued at $5,069,000 after purchasing an additional 22,993 shares in the last quarter. Duality Advisers LP boosted its position in shares of Insulet by 89.4% in the first quarter. Duality Advisers LP now owns 19,131 shares of the medical instruments supplier’s stock worth $3,279,000 after buying an additional 9,029 shares during the period. Diversify Advisory Services LLC purchased a new position in shares of Insulet during the first quarter valued at $1,043,000. Finally, Intech Investment Management LLC raised its position in Insulet by 113.8% during the first quarter. Intech Investment Management LLC now owns 6,649 shares of the medical instruments supplier’s stock valued at $1,140,000 after buying an additional 3,539 shares during the period.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.